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Abstract
Background: Rarity and heterogeneity of liposarcomas (LPS) make their diagnosis difficult even for sarcoma-experts
pathologists. The molecular mechanism underlying the development and progression of liposarcomas (LPS) remains
only partially known. In order to identify and compare the genomic profiles, we analyzed array-based comparative
genomic hybridization (array-CGH) profiles of 66 liposarcomas, including well-differentiated (WDLPS), dedifferentiated
(DDLPS) and myxoid (MLPS) subtypes.
Results: Copy number aberrations (CNAs) were identified in 98% of WDLPS and DDLPS and in 95% of MLPS
cases. The minimal common region of amplification at 12q14.1q21.1 was observed in 96% of WDLPS and DDLPS
cases. Four regions of CNAs, including losses of chromosome 6, 11 and 13 and gains of chromosome 14 were
classified as recurrent in DDLPS; at least one was identified in 74% of DDLPS tumors. The DDLPS-associated
losses were much more common in tumors with increased genomic complexity. In MLPS, the most frequent
CNAs were losses of chromosome 6 (40%) and gains of chromosome 1 (30%), with the minimal overlapping
regions 6q14.1q22.31 and 1q25.1q32.2, respectively.
Conclusions: Our findings show that the application of array-CGH allows to delineate clearly the genomic
profiles of WDLPS, DDLPS and MLPS that reflect biological differences between these tumors. Although CNAs
varied widely, the subtypes of tumors have characteristic genomic profiles that could facilitate the differential
diagnosis of LPS subtypes, especially between WDLPS and DDLPS.
Keywords: Liposarcoma, Array-based comparative genomic hybridization (array-CGH), Copy number aberrations,
Genomic profiling, Genomic imbalances
Background
Liposarcomas (LPS), the most common soft tissue sarco-
mas accounting for less than 1% of all human cancer
cases, display remarkable clinical and pathological hetero-
geneity. Morphologically, liposarcomas are divided into
four main subtypes: well-differentiated (WDLPS), dediffer-
entiated (DDLPS), myxoid/round cell (MLPS/MRLPS)
and pleomorphic liposarcomas (PLPS). WDLPS represents
40–50% of LPS, followed by MLPS (30–35%) [1, 2].
Somatic copy number aberrations (CNAs) occur com-
monly in human cancer and evaluation of their character-
istic patterns may be used as a diagnostic tool, especially
in soft tissue sarcomas [3]. Knowledge of alterations in
genome structure could also facilitate identification of
corresponding oncogenes or tumor suppressor genes
associated with the pathogenesis or progression of the
disease. So far, CNAs in LPS were mostly evaluated using
classical cytogenetic and targeted FISH approaches. It
allowed identification of supernumerary ring giant chro-
mosomes and double-minute chromosomes (dmin) in
WDLPS and DDLS. These chromosomes contain ampli-
fied segments from the 12q13q15 region, including
MDM2, CDK4 and HMGA2 oncogenes. Consequently,
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evaluation of 12q13q15 amplification has been applied
clinically as it allows for distinguishing WDLPS/DDLPS
from benign adipocytic tumors [4, 5]. However, the differ-
ential diagnosis between WDLPS and DDLPS is much
more challenging, because about 10% of DDLPS are the
recurrences of WDLPS as a non-lipogenic sarcoma of
variable histological grade. Little is known about the
molecular mechanism of dedifferentiation and no genetic
alteration has been identified as contributing to this
process yet. Recently, it has been suggested that the num-
ber of dedifferentiation events in LPS could be underesti-
mated and that actually DDLPS might be the most
common histological subtype [6]. MLPS, the third subtype
of LPS, is distinguished by the presence of a specific trans-
location t(12;16) [7] or t(12;22) [8] that is the key genetic
aberration, extremely helpful in differential diagnosis be-
tween MLPS and myxofibrosarcomas [5]. These unique
chromosomal translocations, detected in more than 95%
of cases, result from a fusion of the segments of the
DDIT3 gene (12q13) and the FUS gene (16p11) or the
EWSR1 gene (22q12) [1, 9].
In recent years, the application of high-resolution
methods, such as array-CGH, results in a significant pro-
gress in the whole-genome analysis. A few studies pub-
lished so far have evaluated application of array-CGH
and/or whole exome sequencing (WES) techniques in
the cohort of patients with LPS [9–11]. Tap et al. (2011)
have reported gains in 1p32 with JUN amplification and
6q23 as frequent areas of interest in WDLPS and
DDLPS, whereas the loss of 19q13 is thought to be asso-
ciated with the poorer prognosis [10]. Up to now, no
detailed genomic profiles of MLPS using high - reso-
lution array-CGH method have been published.
In this study, we performed array-based comparative
genomic hybridization (array-CGH) analyses on 69 LPS
tumors aimed at identification of specific patterns of
chromosomal aberrations that reflect biological differ-
ences between these tumors. Accordingly, the diagnostic
value of combining morphology with genetic testing was
estimated in the group of patients with LPS.
Methods
Tumor specimens
In total, 69 fresh-frozen tissue samples from 53 patients
diagnosed with liposarcomas were included in this study:
23 WDLPS (from 18 patients), 23 DDLPS (from 16
patients) and 23 MLPS (from 19 patients). All tissue
samples have been stored in the archives of the Depart-
ment of Biology and Genetics, Medical University of
Gdansk. The histological subtypes and tumor tissue con-
tent of each sample were evaluated independently by
two sarcoma-expert pathologists. The clinicopathological
data (patients’ gender and age, tumor type and its site of
development) are presented in Additional file 1: Table S1.
Briefly, the studied group consisted of 28 primary tumors,
31 local recurrences and ten metastases. The median age
at initial diagnosis was 50 years (range 32–82). The retro-
peritoneum (39%, 27/69) was the most prevalent location
followed by the extremities (33%, 23/69).
DNA extraction
Genomic DNA, after verification of neoplastic cell con-
tent as exceeding 70%, was extracted from a fresh-frozen
tumor tissue sample according to salting-out protocol
[12]. Array-CGH analyses were performed on archival
material. In most cases peripheral blood from patients
was not available, therefore a pool of female DNA, iso-
lated by using QIAamp DNA Blood Midi Kit (Qiagen,
Hilden, Germany), was used as the reference DNA.
Array-CGH analysis
Array-CGH was performed at resolution of 10 kbp using
Human CGH 2.1M Whole-Genome Tilling Array
(NimbleGen, Roche, Basel, Switzerland) following the
instructions provided by manufacturer with modifica-
tion as previously described [13]. Arrays were scanned
at 2 μm with MS200 Microarray Scanner (NimbleGen,
Roche, Basel, Switzerland) and analyzed with Deva
v1.0.2 and Nexus Copy Number 7.5 softwares (Nimble-
Gen, Roche, Basel, Switzerland and BioDiscovery, El
Segundo, CA, USA, respectively). Extracted arrays with
a DRL spread <0.3 were included in the analysis (aver-
age DRLs = 0.15). A minimum of five consecutive
probes were required to define a region as a CNA. All
identified genomic imbalances were verified in the in-
house database, containing >1000 benign copy number
variations (CNVs), identified in local populations as
well as in online database of genomic variants (DGV;
http://dgv.tcag.ca) [14]. Numbering of map positions
was based on hg18 (NCBI36 reference sequence).
Karyotyping and FISH
Cytogenetic studies were performed using conventional
GTG-banding of tumor cells metaphase chromosomes at a
550 band level following standard protocol after the diges-
tion with collagenase [15]. In each analysis from 5 to 30
metaphases were evaluated. In MLPS cases where chromo-
somal translocation t(12;16) or t(12;22) was not noted by
karyotype studies, FISH using Vysis LSI DDIT3 (CHOP)
Dual Color, Break Apart Rearrangement Probe (Abbott
Molecular Inc, Des Plaines, IL, USA) was performed.
Quantitative real-time PCR
Small deletions (<300 kbp) were validated by quantita-
tive real-time PCR (qPCR) performed on Light Cycler
480 System (Roche, Basel, Switzerland) using specific
FAM pre-labelled probes from Universal Probe Library
(Roche, Basel, Switzerland). Target genes within the
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deleted or duplicated regions were assessed against a con-
trol sequence at Xq28 and two reference genes: GPR15
(3q11.2) and ERMP1 (9p24.1). All samples were run in
triplicates. The dosage of target genes relative to reference
genes normalized to control DNA was assessed.
Statistical analysis
For univariate analysis, Fisher’s exact test and Mann-
Whitney test or Kruskal-Wallis test were used to com-
pare categorical and continuous variables, respectively.
Analyses were performed with the STATISTICA 10 soft-
ware (StatSoft Inc, Tulsa, OK, USA).
Results
General overview
Normal karyotype established by classical karyotyping was
observed in 11.6% (8/69) of tumors. Ninety-six percent
(66/69) of tumors were successfully profiled by array-
CGH. The remaining three samples failed the analysis
because of high degree of DNA degradation and were ex-
cluded from further analyses. The detailed list of all aber-
rations detected in each tumor by classic and molecular
cytogenetics is presented in Additional file 2: Table S2.
Genomic imbalances were revealed in 97% of the tu-
mors (Fig. 1), including 98% (45/46) of WDLPS and
DDLPS and 95% (19/20) of MLPS. CNAs affected on aver-
age 9.8% of the genome in DDLPS (range: 0.4–29.2%) vs.
1.9% (range: 0–10.3%) and 3.8% (range: 0–13.3%) in
WDLPS and MLPS, respectively; the difference being
statistically significant (p < 0.001; Kruskal-Wallis test). The
losses were much more common in DDLPS than in
WDLPS (p < 0.001 OR = 0.02 95% Cl [0.002–0.146]), while
no statistically significant difference in number of gains
was observed. No amplification region was observed in
MLPS. The comparison of all tumors, irrespective of the
histological subtype, demonstrated that losses of chromo-
some 6 and gains of chromosome 5 were found more
common in recurrences and metastases than in the
primary tumors (p = 0.009 and p = 0.042, respectively). Be-
sides, the most complex genomic profiles were observed
in recurrences (6.8%; range: 0.1–29.2%), followed by me-
tastases and primary tumors (5.3%; range: 0.7–11.9% and
3.5%; range: 0–24.1%, respectively).
WDLPS/DDLPS
The most frequently affected chromosomal region in
WDLPS and DDLPS was 12q, gained in 44/46 of both
LPS subtypes, with the minimal common region at
12q14.1q21.1. The three peaks of amplification in this
region were localized in the vicinity of CDK4, HMGA2
and MDM2 loci (Fig. 2). These genes were amplified in
95.7, 91.3, 95.7% of WDLPS and 91.3, 87, 91.3% of
DDLPS, respectively.
Besides, the commonly involved chromosomal regions
in WDLPS were gains of short arms of chromosome 5 (9/
23; 39%) and 19 (6/23; 26%) (Fig. 3a). The gain of chromo-
some 19p with the minimal overlapping region of 18 Mbp
at 19p13.3p13.11, encompassing a total number of 586
Fig. 1 Copy number aberrations (CNAs) identified by array-CGH in 66 LPS samples. a Frequency plot of CNAs in all LPS samples. b Heat map of
the CNAs of 66 LPS tumor samples grouped by histological subtypes. Red and blue bars depict percentage of tumors with losses and gains, respectively
in the corresponding region of chromosome. X-axis shows the consecutive chromosome numbers. Color intensity on heat map corresponds to the
normalized fluorescence log2 ratio from array-CGH experiments. Asterisks (*) indicate samples with the normal genome profile established by
conventional karyotyping. Samples denoted by the black frame represent tumors with diagnosis refinement based on array-CGH results
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genes, was more often detected in tumors with in-
creased genomic complexity (p = 0.019; Mann – Whitney
test). In addition, a homozygous deletion of 155 kbp at
8p11.23p11.22, encompassing ADAM3a and ADAM5
genes, was found in 10 of 23 (44%) WDLPS tumors.
Quantitative PCR analysis of matched tumor and normal
tissue samples revealed constitutional and not somatic
character of this aberration. The overall frequency of this
CNV in in-house population-matched database has been
estimated at 6.5%.
DDLPS were characterized by more numerous aberra-
tions than WDLPS, the most common being losses of
chromosomes 13 and 15 (Fig. 3b). The deletions of the
long arms of chromosome 15 were found exclusively in
the local recurrences (6/23; 26%), while aberrations of
chromosome 13, identified in 30% of DDLPS (7/23),
Fig. 2 Array-CGH profile of chromosome 12 in WDLPS and DDLPS tumors. a Penetrance plots of copy number aberrations (CNAs) in 46 cases of
WDLPS and DDLPS. b Examples of genomic imbalances on chromosome 12 detected by array-CGH. Blue bars indicate the percentage of tumors
with an amplification in the corresponding region of the chromosome 12. Black arrows depict three peaks of amplification in this region with
CDK4, HMGA2 and MDM2 loci. Increased resolution of array-CGH technique allowed for the establishing the amplification level of known oncogenes
associated with WD/DDLPS pathogenesis
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were characteristic for tumors located in the abdomen
(p = 0.058 and p = 0.002, respectively). The minimal
overlapping region of 65 Mb at 13q11q31.1 covered a total
number of 382 genes, among which nine genes are known
to be associated with cancer pathogenesis (ZMYM2,
CDX2, FLT3, BRCA2, LHFP, TTL, FOXO1, LCP1, RB1). In
addition, the losses of chromosome 11 and 13, found
exclusively in DDLPS, were more frequently observed
in the DDLPS tumors with increased genomic complexity
(p= 0.027 and p= 0.049, respectively; Mann – Whitney test).
Genomic aberrations present considerably more
(i.e. by at least 30%) often in DDLPS than in WDLPS
have been classified as DDLPS-associated (Table 1).
These included: losses of chromosome 6, 11 and 13q
and gains of chromosome 14q. At least one of the
DDLPS-associated CNA was identified in 74% of DDLPS
tumors (17/23); while two such CNAs were present in
39% (9/23) and three or more in 13% (3/23) of DDPLS.
MLPS
The presence of the specific genomic translocation
t(12;16) was identified in 18 of 20 MLPS tumors (90%)
by standard diagnostic testing, including karyotype and/
or FISH for DDIT3 locus. The CNAs detected most
often in MLPS were losses of 6q (8/20; 40%) and gains
of 1q (6/20; 30%) (Fig. 3c). The minimal overlapping re-
gion of 36 Mbp at 6q14.1q22.31 covered a total of 175
genes, including four genes from the Cancer Gene
Fig. 3 Comparison of the standard diagnostic approach and array-CGH in WDLPS, DDLPS and MLPS tumors. On the left the conventional
karyotyping and/or FISH results are shown. Black arrows depict the supernumerary ring chromosomes in WDLPS and DDLPS tumors (a–b) and
the balanced translocation t(12;16) in MLPS sample (c). DDIT3 break apart probe was used in FISH analysis (one orange and one green signal
pattern indicate a rearrangement of the DDIT3 gene region). On the right the overview of all copy number aberrations (CNAs) detected by
array-CGH is presented. Red and blue colors represent losses and gains, respectively
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Census database (PRDM1, FOX03, ROS1, GOPC), while
gains of 1q25.1q32.2 of 34 Mbp encompassed a total of
269 genes, among which six genes are known to be in-
volved in cancer pathogenesis (ABL2, TPR, CDC73,
MDM4, ELK4, SLC45A3). Among other CNAs present
in MLPS, trisomy of chromosome 8 (3/20; 15%), 13
(2/20; 10%) and a loss of chromosome 16q (2/20;
10%) were present in more than one case each. No
statistically significant correlations with the type and
the location of tumors were found, but additional copies
of chromosome 1 were more frequently observed in tu-
mors with increased genomic complexity (p = 0.035;
Mann-Whitney test).
Discussion
In the present study, we have performed the comparison
of the genomic profiles established by means of simul-
taneous classical and molecular cytogenetics analyses in
a large series of three LPS subtypes (WDLPS, DDLPS
and MLPS). In addition, we estimated the efficacy of im-
plementation the array-CGH analyses into the panel of
routine diagnostic procedures in LPS. On the other
hand, evaluation of the prognostic significance of par-
ticular chromosomal abnormalities on clinical outcome
of the patients is beyond the scope of current research.
The significantly higher resolution of array-CGH over
conventional karyotyping allowed to detect CNAs in tu-
mors with greater sensitivity and precision. In the
current study, six tumors with apparently normal gen-
omic profiles established by conventional technique were
found to harbor unbalanced chromosomal aberrations.
Certain marker and/or ring chromosomes were large
enough to be identified through light microscope, how-
ever in most cases application of the molecular method
allowed for identification of a number of additional
events. Array-CGH screening test facilitated identifica-
tion of the possible origin of the marker/ring chromo-
somes in 67% (31/46) of WDLPS and DDLPS cases.
Not only small genomic imbalances were identified, but
this technique also allowed for estimation of the amplifica-
tion frequency of specific genes (Fig. 2). Amplification of
12q, commonly observed in WDLPS and DDLPS tumors,
covers loci of several oncogenes, including MDM2, CDK4
and HMGA2 that are proposed to play the role in the mo-
lecular pathogenesis of both subtypes [16]. In the current
study, MDM2, CDK4 and HMGA2 amplifications were
found in ~92% of samples what is in line with previously
reported incidence [1, 4, 9, 10, 17]. Moreover, recently
published data have demonstrated that the 12q14.1q21.1
amplicon may contain the other genes, presumably in-
volved in LPS pathogenesis, such as FRS2 (12q15) or CPM
(12q15) [11, 17–19]. In our series, the frequency of high –
level amplifications of the FRS2 and CPM genes was
somehow lower than previously reported (88% and 85%
vs. 97% and 89%, respectively).
According to the guidelines of the European Sarcoma
Network Working Group the genetic testing should be
the mandatory part of the pathological diagnosis of soft
tissue sarcomas (2014) [20]. As pointed out by Italiano
et al. (2016), molecular genetic screening facilitated es-
tablishing accurate diagnosis in 14% (53/384) sarcoma
cases. The highest rate of misdiagnoses prior to molecular
testing was observed in the DDLPS cohort (23%, 7/30)
[21]. In the current study, initially four WDLPS tumors
(6%) were wrongly classified, but in light of the array-
CGH profiling they were eventually diagnosed as DDLPS
(Fig. 1b and Additional file 2: Table S2). The distinction
between WDLPS and DDLPS is challenging, because both
Table 1 Copy number aberrations associated with DDLPS subtype





(2-tailed Fisher’s exact test)






















Losses of chromosome 13qa 0 7 (30) 0.009
13q11q31.1 0 7 (30) 0.009
Gains of chromosome 14q 3 (13) 10 (43) 0.047
OR = 0.2 95% Cl [0.05–0.85]
14q21.2q21.3 2 (9) 9 (39) 0.035
OR = 0.2 95% Cl [0.03–0.79]
14q32.2q32.31 2 (9) 2 (9) 1
aCNAs associated with increased genomic complexity of DDLPS tumors
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are characterized by the presence of ring and marker
chromosomes and 12q14q15 amplification, established
routinely by conventional karyotyping and FISH, respect-
ively (Fig. 3). The application of array-CGH allowed to
identify the specific set of genomic imbalances in DDLPS
(Table 1; Fig. 3b) that could be used as specific marker in
differential diagnosis with WDLPS. Losses of chromo-
somes 11 and 13, associated with increased genomic com-
plexity of tumors, were observed exclusively in DDLPS.
These CNAs encompass a number of cancer-associated
genes, among which a few have already been proposed as
candidate genes in the pathogenesis of soft tissue sarco-
mas, i.e. RB1 [22]. It has been demonstrated that 16% of
lipomas, benign fatty tumors, have harbored 13q14 losses,
while in spindle cell lipomas the frequency of this aberra-
tion is almost 100% [23, 24]. Moreover, the coexistence of
retinoblastoma and lipoma/liposarcoma was observed in
sporadic cases, even though the role of the RB1 gene in
their pathogenesis and differentiation process remains still
unknown [25, 26]. The other CNAs that are nearly specific
to DDLPS included gains of chromosome 14q and losses
of chromosome 6.
Overall, genomic imbalances were far more numerous
in the DDLPS tumors than in WDLPS (5x) and MLPS
(2.5x). Previously, Crago et al. (2012) have shown that
WDLPS and DDLPS had more CNAs, affecting 5.7%
and 21% of the genome, respectively [10]. The difference
in the reported genomic complexity between theirs and
the current study may be explained by the localization
of tumors. Most of the neoplasms (89%) presented in
their study were located in the retroperitoneum that is
associated with poorer prognosis, compared with only
39% of such tumor location in our study.
So far, trisomy of chromosome 8 [22, 27–29] and 13q
gains [30] have been reported as the CNAs with the
highest prevalence in MLPS. The additional copies of
chromosome 13 have been suggested to correlate with
poorer prognosis of MLPS patients [30]. However, these
observations were not in line with our results; gains of
chromosome 8 and 13 were identified only in three and
two tumors, respectively. The most frequently involved
chromosomal regions in MLPS were losses of chromo-
some 6 and gains of chromosome 1 (Fig. 3c).
Most neoplasm disorders are characterized by chromo-
somal instability (CIN) that is defined as a genomic in-
stability with observed high rate of chromosomal losses
and/or gains. Even though CIN is typical for the vast ma-
jority of human cancers, its exact contribution to tumor
progression is still deliberated [31]. An increasing number
and size of genomic alterations from a primary tumor to
its metastasis was confirmed by our studies. Nearly two-
fold increase in genomic complexity in recurrences and
metastases was observed, compared with the primary
tumors. Moreover, array-CGH analysis revealed that
losses of chromosome 6 and gains of chromosome 5
were observed more frequently in the recurrences and
metastases than in the primary LPS tumors regardless
of their histological subtype.
The number of technical difficulties faced during cyto-
genetic chromosome preparations, such as high inci-
dence of cell culture failures, contamination or normal
cell growth may be overcome by using array-CGH.
Array-CGH appears as a less time-consuming (analysis
can be performed within 72 h) and a cost-effective
genome-wide screening tool. Notwithstanding the afore-
said, array-CGH has several limitations. First of all, it
does not detect balanced translocations, inversions or
point mutations. In order to assess the presence of the
specific balanced translocations t(12;16) or t(12;22) in
MLPS tumors, classical karyotyping and/or targeted
FISH has to be nonetheless performed. Furthermore,
fresh frozen material is the preferred source of DNA for
array-CGH analyses, because paraffin- embedded tissue
(FFPE) specimens often increase experimental noise [32]
leading to an elevated rate of false positive CNAs calls.
That is contrary to the standard pathological procedures
that prefer FFPE over fresh-frozen samples. Moreover,
tumor DNA may be contaminated with DNA from non-
neoplastic cells, and even the tumor cells are histologi-
cally and genetically heterogeneous. To avoid masking of
acquired aberrations by normal tissue DNA it has been
strongly suggested to ensure at least 25% of tumor cells
in sample [33]. Constitutional normal DNA from the
patient with tumor sample has been recommended as
reference in array-CGH analysis, however in clinical
practice it is difficult to achieve. Accordingly, to distin-
guish clonal from constitutional aberrations each abnor-
mality should be verified in the databases of polymorphic,
benign copy number variations (CNVs). In this study, the
homozygous deletion at 8p11.23p11.22, encompassed
ADAM3a and ADAM5 genes, was observed in 42% cases
of WDLPS tumors. Losses of 8p11.23p11.22 have been
also identified in 16% of pediatric high-grade gliomas
[34] and 7% of the non-small cell lung cancer samples
that have been suggested to be correlated with poorer
prognosis of these patients [35]. However, we demon-
strated that this aberration was observed in both normal
tissue and the tumor sample, implying the possibility of
occurrence of nonpathogenic copy number variation
(CNV) what is consistent with the findings of Li et al.
[36]. Hence, it is essential to accurately identify somatic
aberrations in cancer profile genome to exclude the
critical errors that may cause data to be misleadingly
interpreted.
Conclusion
In conclusion, the application of array-CGH allowed to
delineate clearly the genomic profiles of WDLPS,
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DDLPS and MLPS that reflect biological differences
between these tumors. We demonstrate that knowledge
of the genome profile along with the detailed histological
examination may help to reduce misdiagnoses of LPS
subtypes. Specific set of genomic changes, established by
array-CGH in DDLPS may facilitate diagnostic dilemma.
In order to assess the significance of these alterations in
LPS patients, further extensive studies on well-defined
larger cohorts and correlations with clinical data should
be conducted. In addition, we provide the evidence that
array-CGH is an appropriate complementary method to
standard diagnostic approach of conventional karyotyping
and FISH, however the implementation of high-resolution
profiling in routine diagnostic practice should be under-
taken selectively.
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